Icrucumab (IMC-18F1)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Icrucumab (IMC-18F1), covering 2019-08-14 to 2019-08-14. Get the full timeline:
Most recent: Clinical Trial Update: Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients [Phase 2]